Spass Inc

We are dedicated to developing medical AI solutions to revolutionize the medical industry. Time is a limited resource for everyone, especially in a hospital setting where life teeters on the brink between life or death. In the face of limited time, staff, and systems, there have been instances where healthcare providers have been unable to reach patients in need of treatment. To address situations where medical practitioners cannot reach patients in need of treatment, Spass provides medical AI solutions, ensuring medical practitioners are able to connect with their patients anytime and anywhere. In 2023, Spass was recognized as a 'Baby Unicorn' company, with an estimated valuation exceeding 1 trillion KRW, and obtained FDA approval for AI-based sepsis diagnosis solutions. These achievements demonstrate that Spass possesses top-tier innovative technology and execution capabilities. At Spass, we strive to go beyond these results, making it our ultimate goal to enrich the world and produce advancements through technology. We are committed to ensuring that no patient’s life goes unnoticed.